US 10064845
Compositions and methods of treating muscular dystrophy with thromboxane-A2 receptor antagonists
granted A61KA61K31/422A61P
Quick answer
US patent 10064845 (Compositions and methods of treating muscular dystrophy with thromboxane-A2 receptor antagonists) held by Cumberland Pharmaceuticals Inc. expires Mon Aug 30 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Cumberland Pharmaceuticals Inc.
- Grant date
- Tue Sep 04 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 30 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 22
- CPC classes
- A61K, A61K31/422, A61P, A61P1/00, A61P1/04